Valuation: Insulet Corporation

Market Cap 9.92B 8.5B 7.95B 7.27B 13.73B 946B 13.85B 93.76B 36.55B 477B 37.25B 36.44B 1,580B P/E 2026 *
23.3x
P/E 2027 * 18.7x
Enterprise Value 9.97B 8.54B 7.99B 7.31B 13.79B 951B 13.92B 94.23B 36.73B 479B 37.44B 36.62B 1,588B EV / Sales 2026 *
3.03x
EV / Sales 2027 * 2.56x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day-1.63%
1 week+2.40%
Current month-13.49%
1 month-12.38%
3 months-7.63%
6 months-41.67%
Current year-49.67%
1 week 141.78
Extreme 141.78
155.17
1 month 126.4
Extreme 126.4
172.92
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 2025-04-27
Director of Finance/CFO 53 2025-09-29
Compliance Officer 50 2022-11-30
Director TitleAgeSince
Chairman 61 2018-12-31
Director/Board Member 61 2015-07-26
Director/Board Member 59 2017-08-09
Date Insider Type Main position Quantity % Market Cap.
8/21/26 Buy

Chief Executive Officer

1,100 0.0016%
8/1/26 Tax

Head of Human Resources

-244 0.0003%
7/1/26 Free

Director

1,355 0.0019%
Change 5-day change 1-year change 3-year change Capi.($)
-1.63%+2.40%-56.75%-23.84% 10.09B
-0.46%+5.22%-12.41%+11.93% 202B
-1.89%+0.60%-1.69%+12.44% 119B
+1.33%+4.97%+12.12%+83.51% 61.78B
+0.40%-5.32%+30.83%+55.98% 52.35B
-0.50%+4.22%-4.95%-31.49% 51.96B
-2.09%+0.45%+8.39%-11.71% 34.36B
+2.71%+2.18% - - 30.44B
-1.37%+0.54%+40.60%-11.04% 24.87B
+0.04%-0.90%-5.19%+24.89% 24.07B
Average -0.08%+1.72%+1.22%+12.30% 61.07B
Weighted average by Cap. +0.09%+2.85%-0.00%+17.27%

Financials

2026 *2027 *
Net sales 3.29B 2.82B 2.64B 2.41B 4.55B 314B 4.59B 31.07B 12.11B 158B 12.34B 12.07B 524B 3.74B 3.21B 3B 2.74B 5.18B 357B 5.23B 35.39B 13.79B 180B 14.06B 13.75B 596B
Net income 427M 365M 342M 313M 590M 40.7B 596M 4.03B 1.57B 20.51B 1.6B 1.57B 67.94B 535M 459M 429M 392M 741M 51.07B 747M 5.06B 1.97B 25.74B 2.01B 1.97B 85.25B
Net Debt 49.62M 42.51M 39.79M 36.36M 68.65M 4.73B 69.27M 469M 183M 2.39B 186M 182M 7.9B -322M -276M -258M -236M -446M -30.75B -450M -3.05B -1.19B -15.5B -1.21B -1.18B -51.34B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
26-08-25 US$143.05 -1.63% 1,925,451
26-08-24 US$145.42 -1.85% 1,568,557
26-08-21 US$148.16 +0.88% 903,610
26-08-20 US$146.87 -3.06% 1,212,723
26-08-19 US$151.51 +2.35% 1,311,497
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
145.42USD
Average target price
171.91USD
Spread / Average Target
+18.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock